Elemental Formula denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for elemental formula are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Elemental Formula Citing FDA Approval — and How to Respond

A "not-FDA-approved" denial in the context of elemental formula reflects an important regulatory distinction that your appeal can clarify: elemental formulas are not drugs requiring FDA drug approval. They are categorized as medical foods or dietary products and are subject to a different regulatory framework than prescription pharmaceuticals. Humana's denial may stem from a miscategorization in its claims system, or from a coverage policy that applies drug-approval standards incorrectly to a medical food product. This type of denial is often resolvable by clarifying the correct regulatory classification.

## Why This Denial Is Appealable

The FDA regulates elemental formulas as medical foods under a framework that does not require the same pre-market approval pathway as prescription drugs. If Humana's denial rests on a pharmaceutical drug-approval standard that does not apply to the product category, the entire legal and policy basis for the denial is incorrect. Your appeal should document the correct regulatory status of the specific product and demonstrate that Humana's own coverage policy, properly applied to medical foods, covers the product for your diagnosed condition.

## Your Federal Appeal Rights

• Internal appeal: ERISA §503 (employer plans) or state insurance law provides the right to a full-and-fair internal review. File within the deadline on your denial letter, typically 180 days.
• External review: ACA §2719 entitles most members to an independent external review within approximately four months of a final internal denial. An external reviewer who understands the regulatory distinction is well-positioned to overturn an incorrectly applied drug-approval standard.
• Expedited review: If waiting would cause serious clinical harm, request expedited processing at both stages.

## What to Gather Before You File

1. Denial letter — the exact policy language invoking FDA approval and the product code or identifier Humana used. 2. Product regulatory documentation — obtain from the manufacturer documentation confirming the product's regulatory classification as a medical food. This is your foundation for rebutting the FDA-approval characterization. 3. Humana's coverage policy — request the full policy document governing medical foods and enteral nutrition. Confirm what regulatory standard it actually requires for this product category. 4. Prescriber's medical-necessity letter — should confirm the diagnosis, the clinical necessity for elemental formula, and identify the product's appropriate regulatory category. 5. Diagnosis and clinical records — chart documentation confirming the condition for which elemental formula is medically indicated. 6. Relevant professional society support — your prescriber can reference the applicable clinical society or guideline organization that recognizes elemental formula as a standard of care for your diagnosed condition.

## Criteria-Mapping Structure

| Basis of Denial | Your Rebuttal Evidence | |---|---| | Product claimed to lack FDA drug approval | [Manufacturer regulatory classification document; FDA medical food framework reference] | | Correct regulatory standard for product category | [Humana policy language on medical foods vs. drugs] | | Clinical necessity for this patient | [Prescriber letter + diagnosis records] | | Coverage under applicable benefit category | [Policy language covering enteral nutrition or medical foods] |

Clarifying the regulatory framework — that elemental formula is not subject to pharmaceutical drug-approval standards — combined with documentation of medical necessity, is typically sufficient to unwind a not-FDA-approved denial that was based on a product misclassification.